Egg-Independent Influenza Vaccines and Vaccine Candidates

Manini, Ilaria; Trombetta, Claudia Maria; Lazzeri, Giacomo; Pozzi, Teresa; Rossi, Stefania; Montomoli, Emanuele

doi:10.3390/vaccines5030018

Cited by 51 publications

(45 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the slow production time and limited production capacity of using embryonated hen's eggs, traditional influenza vaccine manufacturers are not equipped to respond timeously, or in sufficient volume, to a pandemic outbreak (D'Aoust et al, 2010;Quan et al, 2016). Typical egg-based production of split virion vaccines can take up to 6 months due to the limitations inherent in the production platform which can be further hampered by variable production yields (Manini et al, 2017). In contrast, Medicago Inc in the USA has reported the production of a fully formulated HA VLP vaccine within 21 days from the release of the sequence for the pandemic A/H1N1(A/California/04/09) strain (D'Aoust et al, 2010).…”

Section: Influenzamentioning

confidence: 99%

Production of complex viral glycoproteins in plants as vaccine immunogens

Margolin

Chapman

Williamson

et al. 2018

Plant Biotechnology Journal

View full text Add to dashboard Cite

SummaryPlant molecular farming offers a cost‐effective and scalable approach to the expression of recombinant proteins which has been proposed as an alternative to conventional production platforms for developing countries. In recent years, numerous proofs of concept have established that plants can produce biologically active recombinant proteins and immunologically relevant vaccine antigens that are comparable to those made in conventional expression systems. Driving many of these advances is the remarkable plasticity of the plant proteome which enables extensive engineering of the host cell, as well as the development of improved expression vectors facilitating higher levels of protein production. To date, the only plant‐derived viral glycoprotein to be tested in humans is the influenza haemagglutinin which expresses at ~50 mg/kg. However, many other viral glycoproteins that have potential as vaccine immunogens only accumulate at low levels in planta. A critical consideration for the production of many of these proteins in heterologous expression systems is the complexity of post‐translational modifications, such as control of folding, glycosylation and disulphide bridging, which is required to reproduce the native glycoprotein structure. In this review, we will address potential shortcomings of plant expression systems and discuss strategies to optimally exploit the technology for the production of immunologically relevant and structurally authentic glycoproteins for use as vaccine immunogens.

show abstract

Section: Influenzamentioning

confidence: 99%

Production of complex viral glycoproteins in plants as vaccine immunogens

Margolin

Chapman

Williamson

et al. 2018

Plant Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…For instance, an SRMA by Liao et al [76] found that a booster did not have any beneficial effect on the immune response in patients on hemodialysis or peritoneal dialysis or in renal transplant recipients. Moreover, the novel egg-independent technologies with several potential advantages are becoming increasingly common [77,78] and should be further investigated also from the immunogenicity point of view.…”

Section: Discussionmentioning

confidence: 99%

Mapping Host-Related Correlates of Influenza Vaccine-Induced Immune Response: An Umbrella Review of the Available Systematic Reviews and Meta-Analyses

et al. 2019

Self Cite

View full text Add to dashboard Cite

Seasonal influenza is the leading infectious disease in terms of its health and socioeconomic impact. Annual immunization is the most efficient way to reduce this burden. Several correlates of influenza vaccine-induced protection are commonly used, owing to their ready availability and cheapness. Influenza vaccine-induced immunogenicity is a function of host-, virus-and vaccine-related factors. Host-related factors constitute the most heterogeneous group. The objective of this study was to analyze the available systematic evidence on the host factors able to modify influenza vaccine-induced immunogenicity. An umbrella review approach was undertaken. A total of 28 systematic reviews/meta-analyses were analyzed-these covered the following domains: intravenous drug use, psychological stress, acute and chronic physical exercise, genetic polymorphisms, use of pre-/pro-/symbiotics, previous Bacillus Calmette-Guérin vaccination, diabetes mellitus, vitamin D supplementation/deficiency, latent cytomegalovirus infection and various forms of immunosuppression. In order to present effect sizes on the same scale, all possible meta-analyses were re-performed and cumulative evidence synthesis ranking was carried out. The meta-analysis was conducted separately on each health condition category and virus (sub)type. A total of 97 pooled estimates were used in order to construct an evidence-based stakeholder-friendly map. The principal public health implications are discussed.

show abstract

“… Milestones in the history of influenza vaccines [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ]. IIV, inactivated influenza vaccine; WHO, World Health Organization; LAIV, live attenuated influenza vaccine.…”

Section: Figurementioning

confidence: 99%

The Future of Influenza Vaccines: A Historical and Clinical Perspective

Bouvier

2018

Vaccines

View full text Add to dashboard Cite

For centuries, the development of vaccines to prevent infectious disease was an empirical process. From smallpox variolation in Song dynasty China, through the polysaccharide capsule vaccines developed in the 1970s, vaccines were made either from the pathogen itself, treated in some way to render it attenuated or non-infectious, or from a closely related non-pathogenic strain. In recent decades, new scientific knowledge and technologies have enabled rational vaccine design in a way that was unimaginable before. However, vaccines optimal against some infectious diseases, influenza among them, have remained elusive. This review will highlight the challenges that influenza viruses pose for rational vaccine design. In particular, it will consider the clinically beneficial endpoints, beyond complete sterilizing immunity, that have been achieved with vaccines against other infectious diseases, as well as the barriers to achieving similar success against influenza.

show abstract

Egg-Independent Influenza Vaccines and Vaccine Candidates

Cited by 51 publications

References 31 publications

Production of complex viral glycoproteins in plants as vaccine immunogens

Production of complex viral glycoproteins in plants as vaccine immunogens

Mapping Host-Related Correlates of Influenza Vaccine-Induced Immune Response: An Umbrella Review of the Available Systematic Reviews and Meta-Analyses

The Future of Influenza Vaccines: A Historical and Clinical Perspective

Contact Info

Product

Resources

About